Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors
- PMID: 8387918
- PMCID: PMC413430
- DOI: 10.1002/j.1460-2075.1993.tb05857.x
Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors
Abstract
We have analyzed the DNA sequence requirements for cleavage of a 30 bp oligonucleotide that contains a strong bacteriophage T4 type II topoisomerase site. A novel method was used to generate substrates with each of the four nucleotides at 10 positions surrounding the cleavage site, and mutant substrates were also prepared for the four internal positions of the staggered cleavage site. The substrates were tested for cleavage in the presence of several inhibitors that induce enzyme-mediated cleavage: four antitumor agents of different classes (an aminoacridine, a substituted anthraquinone, an ellipticine derivative and an epipodophyllotoxin) and one antibacterial quinolone. At eight nucleotide positions flanking the cleavage site, the same preferred bases were found regardless of which inhibitor was present. These preferred bases show dyad symmetry with respect to the cleavage site, indicating that both protomers of the topoisomerase homodimer interact with DNA in an analogous manner. In addition, we found that the preferred bases on the 5' side of each cleaved phosphodiester bond are highly specific to the inhibitor used in the cleavage reaction. These results strongly suggest that the inhibitors interact directly with the DNA bases at the cleavage site, placing the inhibitor binding site precisely at the site of DNA cleavage.
Similar articles
-
An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.Mol Cell Biol. 2000 Jan;20(2):594-603. doi: 10.1128/MCB.20.2.594-603.2000. Mol Cell Biol. 2000. PMID: 10611238 Free PMC article.
-
A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.Biochemistry. 2002 Jun 25;41(25):7989-97. doi: 10.1021/bi025897m. Biochemistry. 2002. PMID: 12069589
-
A bacteriophage model system for studying topoisomerase inhibitors.Adv Pharmacol. 1994;29B:171-86. doi: 10.1016/s1054-3589(08)61137-0. Adv Pharmacol. 1994. PMID: 8996607 Review.
-
Bacteriophage T4, a model system for understanding the mechanism of type II topoisomerase inhibitors.Biochim Biophys Acta. 1998 Oct 1;1400(1-3):339-47. doi: 10.1016/s0167-4781(98)00145-6. Biochim Biophys Acta. 1998. PMID: 9748648 Review.
-
Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.Mol Pharmacol. 1995 Aug;48(2):238-49. Mol Pharmacol. 1995. PMID: 7651357
Cited by
-
Topoisomerase II-mediated site-directed alkylation of DNA by psorospermin and its use in mapping other topoisomerase II poison binding sites.Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13531-6. doi: 10.1073/pnas.95.23.13531. Proc Natl Acad Sci U S A. 1998. PMID: 9811834 Free PMC article.
-
Position-specific effect of ribonucleotides on the cleavage activity of human topoisomerase II.Nucleic Acids Res. 2000 Dec 15;28(24):4815-21. doi: 10.1093/nar/28.24.4815. Nucleic Acids Res. 2000. PMID: 11121471 Free PMC article.
-
Repair of topoisomerase-mediated DNA damage in bacteriophage T4.Genetics. 2001 May;158(1):19-28. doi: 10.1093/genetics/158.1.19. Genetics. 2001. PMID: 11333215 Free PMC article.
-
Position-specific trapping of topoisomerase II by benzo[a]pyrene diol epoxide adducts: implications for interactions with intercalating anticancer agents.Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12498-503. doi: 10.1073/pnas.2032456100. Epub 2003 Oct 1. Proc Natl Acad Sci U S A. 2003. PMID: 14523238 Free PMC article.
-
Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex.Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11007-11. doi: 10.1073/pnas.91.23.11007. Proc Natl Acad Sci U S A. 1994. PMID: 7971998 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources